The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRVO | +132.88% | -94.93% | -44.91% | -33% |
| S&P | +14.43% | +77.25% | +12.13% | +59% |
Operates as a biopharmaceutical company that develops novel therapies
No news articles found for CervoMed.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $322.57K | -83.4% |
| Market Cap | $74.85M | -37.9% |
| Market Cap / Employee | $4.99M | 0.0% |
| Employees | 15 | 0.0% |
| Net Income | -$7,726.64K | -62.5% |
| EBITDA | -$8,044.20K | -49.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.44M | 21.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -64.37% | -25.1% |
| Return On Invested Capital | -73.39% | 3.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6,465.21K | -33.2% |
| Operating Free Cash Flow | -$6,465.21K | -33.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.42 | 2.03 | 1.58 | 2.24 | -15.22% |
| Price to Sales | 2.02 | 8.55 | 7.23 | 12.15 | -3.72% |
| Price to Tangible Book Value | 0.42 | 2.03 | 1.58 | 2.24 | -15.22% |
| Enterprise Value to EBITDA | 2.66 | -8.37 | -3.43 | -5.91 | -60.32% |
| Return on Equity | -69.9% | -93.4% | -54.2% | -71.4% | 65.02% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
